key: cord-0862300-d66fzsnm
authors: Bailie, Christopher R; Tseng, Yeu-Yang; Carolan, Louise; Kirk, Martyn D; Nicholson, Suellen; Fox, Annette; Sullivan, Sheena G
title: Trend in sensitivity of SARS-CoV-2 serology one year after mild and asymptomatic COVID-19: unpacking potential bias in seroprevalence studies
date: 2022-01-13
journal: Clin Infect Dis
DOI: 10.1093/cid/ciac020
sha: 621dec35ae0b1acf2b5c51576f1241d6763d1f8a
doc_id: 862300
cord_uid: d66fzsnm

A key aim of serosurveillance during the COVID-19 pandemic has been to estimate the prevalence of prior infection, by correcting crude seroprevalence against estimated test performance for PCR-confirmed COVID-19. We show that poor generalisability of sensitivity estimates to some target populations may lead to substantial underestimation of case numbers.

A c c e p t e d M a n u s c r i p t 4

During the current SARS-CoV-2 pandemic, public health agencies have used serology to investigate the clinical spectrum, distribution, and determinants of COVID-19 across time and place to inform a range of interventions *1+. Serology is the preferred method for determining past infection with SARS-CoV-2, because pathogen-specific antibodies are detectable in serum long after clearance of viral RNA or antigen from accessible sites *1+.

The prevalence of prior infection (PPI) has been estimated from cross-sectional sero-surveys, corrected for test sensitivity and specificity against PCR-confirmed infection *2+. However, there are two obvious limitations of this approach.

First, serological assay sensitivity estimates have primarily been derived using samples obtained from symptomatic-usually hospitalised-patients *3-6+. Yet a large proportion of cases have only mild illness, and more than one-third remain asymptomatic *7+. Given the strong correlation between COVID-19 severity and magnitude of antibody response *8, 9+, sensitivity estimates derived from moderately and severely ill patients may not represent the broader SARS-CoV-2-infected population.

Second, most sensitivity estimates are based on samples obtained in early convalescence *3-5+, yet serum antibodies have been shown to decline substantially within a few months of infection *10+. The kinetics of antibody decay may differ between mild and severely ill patients. Nevertheless, antibody decay is not considered in most published seroprevalence estimates.

A c c e p t e d M a n u s c r i p t 5 In light of these limitations, we hypothesised that estimates from seroprevalence studies would underestimate PPI because of differences between test sensitivity in target populations and sensitivity estimates used for correction. To assess the possible magnitude of this bias, we investigated the longitudinal trend in results of one commercial serological assay in a cohort of individuals with mild and asymptomatic COVID-19 over one year, and modelled changes in sensitivity.

The cohort consisted of 48 older adults (median age 67 years, range 36-81), recruited from a previously-described group exposed to SARS-CoV-2 on an Antarctic cruise *11+, with SARS-CoV-2 infection confirmed by PCR and/or serology (Supplementary table S2 Longitudinal analysis of antibody data requires estimating time since infection or disease onset, a challenging prospect for asymptomatic individuals. This cohort were almost certainly all exposed to SARS-CoV-2 over a 4-week period, between boarding the ship on 15

March 2020 and entering a managed quarantine facility in Australia on April 12 2020 *11+. All symptomatic participants became ill between 20 March and 3 April 2020, with the median date of onset 24 March (Figure 1a ). For symptomatic participants we considered date of A c c e p t e d M a n u s c r i p t 6 disease onset to be the same as symptom onset. For asymptomatic participants we set the date of disease onset to the median date of symptom onset, an assumption which is necessarily imprecise at the individual level but which we expected, on average, to hold true for the cohort.

We tested samples using the EUROIMMUN (EI) Anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA) kit for the detection of immunoglobulin G (IgG), as per the manufacturer's instructions. The EI kit uses recombinant S1 domain of SARS-CoV-2 spike as antigen *3+. Results are expressed as the ratio of the measured optical density (OD) for the sample to that of a supplied calibrator, with ratios ≥ 1.1 considered positive. Published sensitivity estimates for samples obtained >14 days after symptom onset range from about 70-100%, and specificity 97-100% *3-6+.

We modelled OD ratios obtained using the EI IgG kit in a hierarchical mixed-effects framework, using a non-linear model proposed by Simonsen et al. *12+. The model accommodates an initially rapid but gradually diminishing increase in antibody from disease onset, followed by exponential decay towards a steady state level *12+. To simulate the longitudinal trend in test sensitivity, we used parameter estimates from the fitted model to construct a hypothetical population of 1000 infected individuals. We simulated OD ratios for these individuals over a three year period from disease onset, and calculated sensitivity as the proportion of individuals with an OD ratio ≥1.1. We constructed 95% confidence In order to roughly estimate the possible degree of bias in these findings, we considered the following simplistic assumptions: 1). All infected individuals had onset of disease on 15

September 2020, the date of peak reported cases in India's first wave *14+; 2). All individuals in the study were sampled on 24 December, 100 days later; 3). The temporal profiles of the true sensitivities of the EI and Siemens assays were equivalent; 4). The reported specificity for the Siemens assay was generalizable to the target population.

Our simulation was compatible with a true sensitivity of 74% 100 days post-disease onset.

Correcting the crude seroprevalence for this value and the reported specificity of the Siemens assay gave a PPI of 29.0% (equation 3 in the supplementary material), equivalent to 326,426,000 infected individuals, or an infection-case ratio of 32.1, 1.35 times higher than the initial estimate. Interestingly, Murhekar et al. noted that seropositivity among a subgroup of 664 participants who reported testing positive for SARS-CoV-2 by PCR was only 64%, a finding they suggested might be due to antibody decay *13+.

Our study had several limitations. The age and sex structure of our cohort differed substantially from most serosurveillance target populations. We have previously discussed the possibility of selection bias due to differential participation based on symptoms *11+.

However, given population estimates of a relatively low infection:hospitalisation ratio *15+, and high asymptomatic proportion *13+, we believe our sample to be more applicable to seroprevalence studies than most others used to derive estimates of serological assay sensitivity. Longitudinal trends in sensitivity may vary depending on the assay and target antigen. Our model has not been validated and relies on unverified assumptions including A c c e p t e d M a n u s c r i p t 9 multivariate log-normality in parameter distribution, and continuing exponential decay past one year. Consequently, we intended to illustrate the potential for biased incidence estimates arising from serosurveillance studies, rather than to provide a precise quantification of this bias or a specific correction method.

Conclusion: improving the utility of serosurveillance for COVID-19

In attempting to infer population prevalence of prior COVID-19 from seroprevalence studies, careful consideration should be given to bias due to non-generalisability of assay sensitivity estimates to target populations, leading to substantial underestimation. The effect of this bias increases with time from infection to sampling.

At a minimum, seroprevalence studies seeking to estimate SARS-CoV-2 infection should include sensitivity analyses allowing for much lower test sensitivity than those reported by kit manufacturers. The utility of seroprevalence surveys to infer patterns of COVID-19 might be further improved by the application of methods to recover incidence by applying models of test kinetics to cross-sectional data *12, 16+. Such methods currently require either: 1).

Single cross-sectional surveys using multiple assays with distinct kinetics, with results reported on continuous rather than binary scales, coupled with longitudinal models of test kinetics derived from population-representative cohorts *16+; or 2). Multiple cross-sectional surveys coupled with accurate mortality data *17, 18+. Studies seeking to estimate infection rather than population immunity must now distinguish between vaccine-and infection- 

a payment to ANU for contract research, and provision of the Annual Cost of Foodborne Disease Illness in Australia, AUD$163,392 Food Standards Australia New Zealand, 2021-2022 a payment to ANU for contract research; Acting Chair for TEPHINET Advisory Board unpaid, Member, Advisory Board, National Centre for Immunisation Research and Surveillance unpaid, and Member, Foodborne Disease Burden Epidemiology Reference Group, World Health Organization unpaid. References 1

Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error

EUROIMMUN. Characteristics of EUROIMMUN ELISA for COVID-19 diagnostics

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

Evaluation of the Euroimmun Anti-SARS-CoV-2 ELISA (IgG) serology assay for the detection of anti-SARS-CoV-2 antibodies: Public Health England

Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis

SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike

Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Symptoms and laboratory manifestations of mild COVID-19 in a repatriated cruise ship cohort

Estimation of incidences of infectious diseases based on antibody measurements

SARS-CoV-2 seroprevalence among the general population and healthcare workers in India

An interactive web-based dashboard to track COVID-19 in real time

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Using Combined Diagnostic Test Results to Hindcast Trends of Infection from Cross-Sectional Data

Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys

Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies

Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses

The authors would like to acknowledge Maria Auladell Bernat for assistance with management of biospecimens; Tony Stewart, Lucinda Franklin, Carrie Barnes, and Annaliese van Diemen for their assistance in study planning. Yeu-Yang Tseng is supported by NIH Grant 

A c c e p t e d M a n u s c r i p t 12 A c c e p t e d M a n u s c r i p t 14